Javier Munoz

18PUBLICATIONS
99CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursTraditional Chinese medicine and treatmentsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Apr 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

|Feb 27, 2026
At the Crossroads of Lineage: Secondary Malignancies After CAR-Based Immunotherapy.

Logan Lorentzen, Mazie Tsang, Talal Hilal

|Oct 16, 2025
Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access.

Angel Luis Orosco-Ttamina, Cecilia Arana Yi, Mazie Tsang

|Feb 13, 2025
Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies.

Frederick L Locke, Javier L Munoz, Michael T Tees

|Feb 12, 2025
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study.

Julio C Chavez, Michael Dickinson, Javier Munoz

|Feb 08, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

Steven M Horwitz, Tatyana A Feldman, Jing Christine Ye

Pageof 3

Frequent Collaborators

6 joint publications

Sattva S Neelapu

6 joint publications

David Miklos

6 joint publications

Olalekan Oluwole

5 joint publications

Andre H Goy